Report/Yearbook 2015-2022 on the Terms and Agreements of Global Partnership Agreements in Cancer Diagnostics


DUBLIN–(BUSINESS WIRE)–The report “Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022” has been added to from offer.

The Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive access to offers and contractual documents available for more than 1000 cancer diagnostic offers.

The report presents the reader with a comprehensive review of cancer diagnostics deal trends, major players, key deal values, and deal financials, to understand how, why, and on what terms companies are entering into deals. partnership with Cancer Diagnostics.

The report presents the values ​​of financial transaction terms for Cancer Diagnostics transactions, listed by aggregate value, upfront payments, milestone payments, and royalties, allowing readers to analyze and compare the financial value of transactions.

The central section of the report explores key negotiators in the field of cancer diagnostics partnerships; both the top trading stocks and the most active trading companies in cancer diagnostics are reported, allowing the reader to see who is succeeding in this dynamic trading market.

One of the main highlights of the report is that over 1,000 online transaction records of actual cancer diagnostics transactions, as disclosed by the parties to the transaction, are included near the end of the report in a directory – by AZ company, stage of development, transaction type, therapeutic focus and type of technology – easy to browse. Each transaction record in the report is linked via Weblink to an online version of the transaction.

In addition, when available, the records include contract documents as submitted to the Securities Exchange Commission by the companies and their partners. While many companies look for details on payment terms, the devil is in the details in terms of triggering payments – contract documents provide this information where press releases and databases do not.

A comprehensive set of appendices are provided, organized by Cancer Diagnostics’ AZ partner company, stage of development, type of transaction, and therapeutic focus. Each transaction title is linked via Weblink to an online version of the transaction file and, where applicable, the contract document, providing easy access to each transaction on request.

In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of cancer diagnostic technologies and products.

Key Benefits

The Global Cancer Diagnostics Terms and Partnership Agreements 2015-2022 offer the reader the following key benefits:

  • In-depth understanding of cancer diagnostics transaction trends since 2015

  • Access to master, initial, milestone and royalty data

  • Detailed access to actual cancer diagnostic contracts from major biopharmaceutical companies

  • Identify the most active marketers in cancer diagnostics since 2015

  • Overview of terms included in a Cancer Diagnostics partnership agreement, with concrete examples

  • Understand the key terms of agreement that companies have agreed to in previous agreements

  • Undertake due diligence to assess the suitability of the terms of the agreement you propose for business partners

In Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022, available offers are listed by:

  • A-Z company

  • Face value

  • Stage of development at signing

  • Offer component type

  • Specific therapeutic target

  • Type of technology

The analysis of the actual contractual agreements makes it possible to evaluate the following elements:

  • What specific rights are granted or optional?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the transaction?

  • How are sales and payments audited?

  • What is the duration of the agreement?

  • How are the main terms of the agreement defined?

  • How are IPRs managed and owned?

  • Who is responsible for marketing?

  • Who is responsible for development, supply and manufacturing?

  • How are confidentiality and publication managed?

  • How to settle disputes?

  • Under what conditions can the agreement be terminated?

  • What happens if the owner changes?

  • What sub-licensing and sub-contracting arrangements have been agreed upon?

  • What boilerplate clauses does the company insist on?

  • What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?

  • What jurisdiction does the company insist on for contract law?

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Cancer Diagnostics Transaction Trends

2.1. Introduction

2.2. Cancer Diagnostics partners over the years

2.3. Most Active Negotiators in Cancer Diagnostics

2.4. Cancer Diagnostics partnerships by type of transaction

2.5. Partnerships Cancer Diagnostics by therapeutic area

2.6. Terms of Agreement for Cancer Diagnostics Partnership

2.6.1 Key values ​​of the Cancer Diagnostics partnership

2.6.2 Cancer Diagnostics processes initial payments

2.6.3 Cancer Diagnostics agreement milestone payments

2.6.4 Cancer Diagnostics Royalty Rates

Chapter 3 – Leading Cancer Diagnostic Offerings

3.1. Introduction

3.2. Best Cancer Diagnostics Deals by Value

Chapter 4 – Most Active Negotiators in Cancer Diagnostics

4.1. Introduction

4.2. Most Active Negotiators in Cancer Diagnostics

4.3. Profiles of the most active Cancer Diagnostics partner companies

Chapter 5 – Cancer Diagnostics Contract Negotiation Directory

5.1. Introduction

5.2. Cancer Diagnostics Contract Negotiation Directory

Chapter 6 – Cancer Diagnostics Transactions by Type of Technology

Chapter 7 – Partner Resource Center

7.1. Online partnership

7.2. Partner events

7.3. Further Reading on Dealmaking


Appendix 1 – Cancer diagnostic offerings by AZ company

Appendix 2 – Cancer Diagnostics offers by stage of development

  • Discovery

  • Preclinical

  • Phase I

  • Stage II

  • Phase III

  • Regulatory

  • marketed

  • Formulation

Annex 3 – Cancer Diagnostics transactions by type of transaction

  • Purchase of assets

  • Assignment

  • Big Pharma Licensing

  • Co-development

  • Collaborative R&D

  • Co-market

  • Co-promotion


  • Cross Licensing

  • Development

  • Distribution

  • Purchase of shares

  • Evaluation

  • To agree

  • joint venture

  • Licence

  • Dispute

  • Manufacturing

  • Marketing

  • Transfer of material

  • Option

  • Promotion

  • To research

  • Rules

  • Dilute

  • Licensed

  • Provide

  • Technology transfer

  • Termination

  • guarantee

Appendix 4 – Cancer diagnostic offerings by therapeutic area

Annex 5 – Definitions of types of transactions

Annex 6 – Further reading on dealmaking

Table of numbers

Figure 1: Cancer Diagnostics partnership since 2015

Figure 2: Active Cancer Diagnostics trading activity since 2015

Figure 3: Cancer Diagnostics partnerships by transaction type since 2015

Figure 4: Cancer Diagnostics partnerships by disease type since 2015

Figure 5: Cancer Diagnostics deals with a flagship value

Figure 6: Cancer Diagnostics processes an initial value

Figure 7: Cancer Diagnostics processes a milestone value

Figure 8: Cancer Diagnostics Processes Royalty Rate Value

Figure 9: Top cancer diagnostic transactions by value since 2015

Figure 10: Most active negotiators in cancer diagnostics since 2015

Companies cited

  • Etna

  • Amgen

  • Angle

  • Axela

  • Bayer

  • B&H

  • Ceres

  • COTA


  • Cyprus

  • D-Eye

  • Dako

  • Dell

  • own

  • Falcon

  • fscan

  • GIMDx

  • Slide

  • grail

  • IBM

  • iCAD

  • IPMD

  • Article

  • KEW

  • Lab21

  • Mavig

  • Medx

  • MIODx

  • Nasa

  • Ochin

  • Orot+


  • rock

  • Sebie

  • Seeing

  • TaiRx

  • Take 2

  • lik

  • UPMC

  • ZoBio

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.


Laura Wood, Senior Press Officer
For EST business hours, call 1-917-300-0470

For US/CAN call toll free 1-800-526-8630

For GMT office hours call +353-1-416-8900

Copyright © acrofan/Business Wire All Rights Reserved

Source link


Comments are closed.